3D Medicines Inc HKEX:1244:
ENVAFOLIMAB SUPPLEMENTAL APPLICATION FOR CONDITIONAL-TO-REGULAR APPROVAL TRANSITION ACCEPTED BY NMPA
3D Medicines Inc Says Envafolimab Supplemental Application Accepted By NMPA
Earlier from 3d Medicines
- 3D Medicines Inc Says Zhang Jing Resigns As CFO
- 3D Medicines Says New Drug Application For First-Line Treatment Of Biliary Tract Cancer Of Envafolimab Accepted
- 3D Medicines Says Envafoimab Granted Orphan Drug Designation